<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 09, 2025</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT00077077</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000346368</org_study_id>
    <secondary_id>DAIICHI-927A-PRT006</secondary_id>
    <secondary_id>WSU-085503MP4F</secondary_id>
    <nct_id>NCT00077077</nct_id>
  </id_info>
  <brief_title>DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I Study Of The Combination Of Oral DJ-927 And Capecitabine In Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo</source>
  <brief_summary>
    <textblock>RATIONALE: Drugs used in chemotherapy, such as DJ-927 and capecitabine, use different&#xd;
ways to stop tumor cells from dividing so they stop growing or die. Combining more than&#xd;
one drug may kill more tumor cells.&#xd;
&#xd;
PURPOSE: This phase I trial is studying the side effects and best dose of DJ-927 and&#xd;
capecitabine in treating patients with locally advanced or metastatic solid tumors.</textblock>
  </brief_summary>
  <detailed_description>
    <textblock>OBJECTIVES:&#xd;
&#xd;
Primary&#xd;
&#xd;
  -  Determine the maximum tolerated dose of DJ-927 and capecitabine in patients with&#xd;
     locally advanced or metastatic solid tumors.&#xd;
&#xd;
  -  Determine the dose-limiting and non-dose-limiting toxic effects of this regimen in&#xd;
     these patients.&#xd;
&#xd;
Secondary&#xd;
&#xd;
  -  Determine the toxicity profile of this regimen in these patients.&#xd;
&#xd;
  -  Determine the possible pharmacokinetic interactions of this regimen in these&#xd;
     patients.&#xd;
&#xd;
  -  Determine the antitumor activity of this regimen in these patients.&#xd;
&#xd;
OUTLINE: This is an open-label, dose-escalation, nonrandomized, multicenter study.&#xd;
&#xd;
  -  Course 1: Patients receive oral DJ-927 once on day 1 and oral capecitabine once on&#xd;
     days 0 and 1 and twice daily on days 2-14.&#xd;
&#xd;
  -  Course 2: Patients receive DJ-927 as in course 1 and oral capecitabine twice daily&#xd;
     on days 2-15.&#xd;
&#xd;
  -  Course 3 and all subsequent courses: Patients receive DJ-927 as in course 1 and oral&#xd;
     capecitabine twice daily on days 1-14.&#xd;
&#xd;
All courses repeat every 21 days in the absence of disease progression or unacceptable&#xd;
toxicity.&#xd;
&#xd;
Cohorts of 3-6 patients receive escalating doses of DJ-927 and capecitabine until the&#xd;
maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that&#xd;
at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A minimum of 6&#xd;
patients receive treatment at the MTD.&#xd;
&#xd;
Patients are followed every 3 months.&#xd;
&#xd;
PROJECTED ACCRUAL: A total of 30-40 patients will be accrued for this study within 18&#xd;
months.</textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DJ-927</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>DISEASE CHARACTERISTICS:&#xd;
&#xd;
  -  Histologically or cytologically confirmed solid tumor&#xd;
&#xd;
       -  Locally advanced or metastatic disease&#xd;
&#xd;
  -  Minimally pretreated&#xd;
&#xd;
  -  No symptomatic brain metastases&#xd;
&#xd;
PATIENT CHARACTERISTICS:&#xd;
&#xd;
Age&#xd;
&#xd;
  -  18 and over&#xd;
&#xd;
Performance status&#xd;
&#xd;
  -  ECOG 0-2&#xd;
&#xd;
Life expectancy&#xd;
&#xd;
  -  At least 3 months&#xd;
&#xd;
Hematopoietic&#xd;
&#xd;
  -  Absolute neutrophil count at least 1,500/mm^3&#xd;
&#xd;
  -  Platelet count at least 100,000/mm^3&#xd;
&#xd;
Hepatic&#xd;
&#xd;
  -  SGOT and SGPT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if&#xd;
     liver metastases are present)&#xd;
&#xd;
  -  Bilirubin no greater than 1.5 times ULN&#xd;
&#xd;
Renal&#xd;
&#xd;
  -  Creatinine no greater than 1.5 times ULN&#xd;
&#xd;
Gastrointestinal&#xd;
&#xd;
  -  No prior chronic diarrhea&#xd;
&#xd;
  -  No swallowing and/or malabsorption problems&#xd;
&#xd;
  -  No diarrhea (excess of 2-3 stools/day above normal frequency in the past month)&#xd;
&#xd;
Other&#xd;
&#xd;
  -  Not pregnant or nursing&#xd;
&#xd;
  -  Negative pregnancy test&#xd;
&#xd;
  -  Fertile patients must use effective contraception&#xd;
&#xd;
  -  HIV negative&#xd;
&#xd;
  -  No prior severe or life-threatening hypersensitivity reaction to a taxane or&#xd;
     capecitabine&#xd;
&#xd;
  -  No concurrent serious infection&#xd;
&#xd;
  -  No neuropathy grade 2 or greater&#xd;
&#xd;
  -  No other malignancy within the past 2 years except nonmelanoma skin cancer or&#xd;
     carcinoma in situ of the cervix&#xd;
&#xd;
  -  No other severe or uncontrolled underlying medical disease that would preclude study&#xd;
     participation&#xd;
&#xd;
  -  No psychiatric disorder that would preclude giving informed consent or study&#xd;
     compliance&#xd;
&#xd;
PRIOR CONCURRENT THERAPY:&#xd;
&#xd;
Biologic therapy&#xd;
&#xd;
  -  No concurrent anticancer biologic therapy&#xd;
&#xd;
Chemotherapy&#xd;
&#xd;
  -  Recovered from prior chemotherapy&#xd;
&#xd;
  -  No other concurrent anticancer chemotherapy&#xd;
&#xd;
Endocrine therapy&#xd;
&#xd;
  -  Not specified&#xd;
&#xd;
Radiotherapy&#xd;
&#xd;
  -  Recovered from prior radiotherapy&#xd;
&#xd;
  -  No concurrent anticancer radiotherapy&#xd;
&#xd;
       -  Concurrent localized radiotherapy to a non-indicator lesion for pain relief is&#xd;
          allowed provided other methods of pain control are ineffective&#xd;
&#xd;
Surgery&#xd;
&#xd;
  -  At least 4 weeks since prior major surgery and recovered&#xd;
&#xd;
  -  No prior major surgery in the stomach or small intestine&#xd;
&#xd;
Other&#xd;
&#xd;
  -  At least 4 weeks since prior myelosuppressive therapy&#xd;
&#xd;
  -  More than 28 days since prior investigational drugs (including analgesics and/or&#xd;
     antiemetics)&#xd;
&#xd;
  -  No other concurrent anticancer therapy&#xd;
&#xd;
  -  No other concurrent anticancer cytotoxic therapy</textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris H. Takimoto, MD, PhD, FACP</last_name>
    <affiliation>Cancer Therapy and Research Center, Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Saif MW, Sarantopoulos J, Patnaik A, Tolcher AW, Takimoto C, Beeram M. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Dec;68(6):1565-73. doi: 10.1007/s00280-011-1639-3. Epub 2011 May 6.</citation>
    <PMID>21547572</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2004</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
</clinical_study>
